Mutations in mTOR and PI3K render ccRCC as a metabolic disease [17] as confirmed by the low level of fructose-1,6-bisphosphatase (FBP1) in most ccRCC patients that antagonized glycolytic flux [18]. This evidence concerns the gene FBP1 and metabolic disease.